Celecoxib
- TRADE NAME: Celebrex (Pfizer)
- INDICATIONS: Osteoarthritis, rheumatoid arthritis (adults and juveniles aged 2 years and over), ankylosing spondylitis, acute pain, primary dysmenorrhea
- CLASS: COX-2 inhibitor, Non-steroidal anti-inflammatory (NSAID), Sulfonamide
- HALF-LIFE: 11 hours
ACE inhibitors, Aliskiren, Angiotensin II receptor antagonists, Aspirin, Dexibuprofen, Fluconazole, Furosemide, Lithium, NSAIDs, Warfarin
PREGNANCY CATEGORY: D
pregnancy category C prior to 30 weeks gestation; category D starting at 30 weeks gestation
Celecoxib is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome.
NSAIDs may cause an increased risk of serious cardiovascular and gastrointestinal adverse events, which can be fatal. This risk may increase with duration of use.
Contra-indicated in patients with known hypersensitivity to celecoxib, aspirin, or other NSAIDs; in patients who have demonstrated allergic-type reactions to sulfonamides; in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; and for the treatment of peri-operative pain in the setting of coronary artery bypass graft surgery.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 03/23/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric